Table 2.
Unadjusted association between patient characteristics and grip strength z-score (bivariate analysis)
| Patient characteristics | Difference in mean grip strength z-score | P value |
|---|---|---|
| Age at cysteamine initiation, months | −0.006 | 0.008 |
| Age at inclusion, yr | −0.002 | 0.86 |
| Male sex | −0.9 | 0.0006 |
| History of dialysis | −0.1 | 0.73 |
| History of kidney transplantation | 0.12 | 0.69 |
| Pediatric patients (vs. adults) | 0.24 | 0.68 |
| Type of treatment at inclusion | 0.03 | |
| Immediate release cysteaminea | Reference | |
| Delayed release cysteamineb | −0.64 | |
| Self-reported adherence, % | 0.006 | |
| ≤75 | Reference | |
| >75 | 1.05 | |
| eGFR at inclusion | 0.004 | 0.56 |
eGFR, estimated glomerular filtration rate.
a
Immediate release cysteamine (Cystagon; Mylan Pharmaceuticals, Canonsburg, PA).
b
Delayed release cysteamine (Procysbi; Horizon Therapeutics, Dublin, Ireland).